$VRDN

4 theses

bullish 75%neutral 0%bearish 25%

Avg return (1d)

-1.6%

Win rate (1d)

33% (3 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Oct 23, 2:46 PM ET

$VRDNSEC Form 4bearish

Tousignant Jennifer · Chief Legal Officer at Viridian Therapeutics, Inc.\DE · 65d agono track record yet

Sold 14,212 @ $24.50 avg · $348,194 · 2026-08-19

Form 4: Tousignant Jennifer sold VRDN

Tousignant Jennifer (Chief Legal Officer at Viridian Therapeutics, Inc.\DE) reported an open-market sale of 14,212 shares of VRDN at an average $24.50, roughly $348,194, in a Form 4 filed 2026-08-20.

At post $24.50Now $22.35-8.8% since postedas of Oct 23, 2:46 PM ET

1d-0.9%

3d-0.9%

1w-2.5%

1m-10.2%

3m—

6m—

1y—

View filing on SEC.gov →

$VRDNr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 114d ago31 prior · 63% at 3mo

“long several of these”

5 of the 6 biotech names I posted 5 weeks ago hit their catalyst (and the 1 that hasn't)

FDA approval of veligrotug (Lumvoa) for active and chronic thyroid eye disease validated the clean Phase 3 data and funded-through-profitability thesis. Catalyst executed successfully with stock up 13%.

At post $19.40Now $22.35+15.2% since postedas of Oct 23, 2:46 PM ET

1d—

3d—

1w+4.1%

1m-2.5%

3m+6.1%

6m—

1y—

original post →

$VRDNr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 131d ago31 prior · 63% at 3mo

Upcoming penny stock catalysts for June/July 2026 in Biotech and Pharma

PDUFA decision for veligrotug (thyroid eye disease) in 5 weeks (June 30). Both Phase 3s hit primary and secondary endpoints including first ever Phase 3 showing diplopia resolution. $762M cash funds operations through profitability if approved; pipeline depth with elegrobart Phase 3 positive and Q1 '27 BLA targeted.

At post $16.30Now $22.35+37.1% since postedas of Oct 23, 2:46 PM ET

1d-2.0%

3d+2.0%

1w+8.2%

1m+16.9%

3m+30.3%

6m—

1y—

original post →

$VRDNr/wallstreetbetsDDbullish

u/Buy-NVDA · 166d agono track record yet

Ez money VRDN

Viridian Therapeutics released Phase 3 data for TED showing strong efficacy (p < 0.0001) with a potentially best-in-class safety profile versus Amgen's Tepezza. With $1.1B in cash, institutional backing at $17.00, and a June 30 PDUFA decision as a near-term catalyst, the stock—currently trading below the offering price—has upside to analyst targets of $34+.

At post $17.20Now $22.35+29.9% since postedas of Oct 23, 2:46 PM ET

1d-2.0%

3d+1.3%

1w-6.4%

1m-8.3%

3m+37.2%

6m—

1y—

original post →

End of results.